Skip to content

4D Molecular Therapeutics

US · FDMT #3519 by market cap Listed 2020
12.59 +0.03 +0.24%
Live - 5344 symbols - heartbeat 223s ago · 2026-10-08 08:05
Pre-market 12.00 -4.69%
After-hours 12.59 0.00%
Market cap
695.52M
P/B
1.71
EPS
-2.42
Reader sentiment Are you bullish or bearish on FDMT?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Jefferies Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $21
    Market Newswire · 2026/3/30
  • Rating change
    Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $23
    Market Newswire · 2026/4/13
  • Rating change
    Cantor Fitzgerald Upgrades 4D Molecular Therapeutics(FDMT.US) to Buy Rating, Announces Target Price $20
    Market Newswire · 2026/9/14
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)
    TipRanks · 2026/7/21
  • Rating change
    Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $26
    Market Newswire · 2026/5/9
  • Rating change
    Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $38
    Market Newswire · 2026/3/20
  • Morgan Stanley Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating
    Market Newswire · 2026/9/29
  • BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $33
    Market Newswire · 2026/9/29
  • Chardan Capital Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $25
    Market Newswire · 2026/10/7
  • Rating change
    Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
    TipRanks · 2026/8/14
  • Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
    TipRanks · 2026/9/21
  • Rating change
    Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $33
    Market Newswire · 2026/5/8
  • Rating change
    Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/7/20
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)
    TipRanks · 2026/7/21
  • Rating change
    BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/7/21
  • Cantor Fitzgerald Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating
    Market Newswire · 2026/9/21
  • Rating change
    RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/5/8
  • Rating change
    H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/8/14
  • Rating change
    Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating
    Market Newswire · 2026/8/14
  • Rating change
    A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36
    Market Newswire · 2026/8/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:05:41 · For reference only, not investment advice and not tailored to your situation.